Milvexian

Small molecule

Also known as BMS-986177, JNJ-70033093

Phase 1Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Other / comorbidity
NCT05757869 · Janssen Research & Development, LLC
2023-04-11 – 2026-12-08 · Atrial Fibrillation
What this study did
NCT05702034 · Janssen Research & Development, LLC
2023-02-15 – 2026-10-15 · Ischemic Stroke; Ischemic Attack, Transient
What this study did
NCT05754957 · Janssen Research & Development, LLC
2023-04-07 – 2026-02-06 · Acute Coronary Syndrome
What this study did
Phase 2 (2)
Other / comorbidity
NCT03766581 · Bristol-Myers Squibb
2019-01-27 – 2022-03-31 · Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
What this study did
NCT03891524 · Janssen Research & Development, LLC
2019-06-17 – 2021-04-06 · Arthroplasty, Replacement, Knee
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03000673 · Bristol-Myers Squibb
2017-05-23 – 2017-10-23 · Antithrombotic
What this study did
Phase 1 (20)
Other / comorbidity
NCT05706753 · Janssen Pharmaceutica N.V., Belgium
2023-01-25 – 2023-07-20 · Healthy Female
What this study did
NCT04844424 · Janssen Research & Development, LLC
2021-04-14 – 2022-07-12 · Healthy
What this study did
NCT04569695 · Janssen Research & Development, LLC
2021-03-08 – 2021-12-16 · Healthy
What this study did
NCT04388501 · Janssen Pharmaceutica N.V., Belgium
2021-06-07 – 2021-10-27 · Healthy
What this study did
NCT04965389 · Bristol-Myers Squibb
2021-07-16 – 2021-10-01 · Healthy Volunteers
What this study did
NCT04206488 · Janssen Research & Development, LLC
2020-01-09 – 2021-06-09 · Healthy
What this study did
NCT04448964 · Janssen Research & Development, LLC
2020-06-26 – 2020-11-14 · Healthy
What this study did
NCT04223349 · Janssen Research & Development, LLC
2020-01-10 – 2020-04-08 · Healthy
What this study did
NCT03939702 · Bristol-Myers Squibb
2019-05-02 – 2019-07-11 · Thrombosis
What this study did
NCT03698513 · Bristol-Myers Squibb
2018-10-04 – 2019-02-19 · Healthy Volunteers
What this study did
NCT02982707 · Bristol-Myers Squibb
2018-03-01 – 2018-09-28 · Thrombosis
What this study did
NCT03196206 · Bristol-Myers Squibb
2017-07-13 – 2018-03-04 · Thrombosis
What this study did
NCT03362437 · Bristol-Myers Squibb
2017-11-15 – 2017-12-28 · Thrombosis
What this study did
NCT03341390 · Bristol-Myers Squibb
2017-10-18 – 2017-11-16 · Healthy Volunteers
What this study did
NCT03224260 · Bristol-Myers Squibb
2017-06-28 – 2017-11-07 · Thrombosis
What this study did
NCT02608970 · Bristol-Myers Squibb
2015-12-31 – 2017-07-23 · Thrombosis
What this study did
NCT02902679 · Bristol-Myers Squibb
2016-11 – 2017-06 · Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
What this study did
NCT02959060 · Bristol-Myers Squibb
2016-11 – 2016-12 · Thrombosis
What this study did
NCT02807909 · Bristol-Myers Squibb
2016-07 – 2016-08 · Thrombosis
What this study did

Competitive landscape

This drug's own stage for Stroke Prevention in Atrial Fibrillation: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Milvexian: this drugStage not on recordSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Amrecibart
Phase 1(overall)
Monoclonal antibodyFactor XInot yet gradedNo reviewed efficacy summary in this indication
Abelacimab
—(overall)
Monoclonal antibodyFactor XI/XIa (FXI/FXIa)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Milvexian to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Atrial FibrillationActive not recruiting
Est. primary completion 2026-12-08 · NCT05757869 · CT.gov ↗
What to watch

See the full readout calendar ↗